Cargando…

Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinoma

A retrospective analysis was conducted on data from four open-label, nonrandomised, phase II trials of recombinant interleukin-2 (rIL-2) in patients with metastatic renal cell carcinoma to compare the safety and efficacy of administration by subcutaneous (s.c.) and continuous intravenous (c.i.v.) in...

Descripción completa

Detalles Bibliográficos
Autores principales: Geertsen, P F, Gore, M E, Negrier, S, Tourani, J M, von der Maase, H
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409650/
https://www.ncbi.nlm.nih.gov/pubmed/15026795
http://dx.doi.org/10.1038/sj.bjc.6601709
_version_ 1782155822770421760
author Geertsen, P F
Gore, M E
Negrier, S
Tourani, J M
von der Maase, H
author_facet Geertsen, P F
Gore, M E
Negrier, S
Tourani, J M
von der Maase, H
author_sort Geertsen, P F
collection PubMed
description A retrospective analysis was conducted on data from four open-label, nonrandomised, phase II trials of recombinant interleukin-2 (rIL-2) in patients with metastatic renal cell carcinoma to compare the safety and efficacy of administration by subcutaneous (s.c.) and continuous intravenous (c.i.v.) infusion (n=103 s.c. and n=225 c.i.v.). No statistically significant differences were found between the cohorts in terms of overall response rate (s.c.: 13.6% vs c.i.v.: 12.4%, P=0.77), response duration (s.c.: 9.8 months vs c.i.v.: 10.1 months, P=0.99), and overall survival (P=0.08). Compared with c.i.v. administration, more patients in the s.c. cohort experienced stable disease (50.5 vs 29.8%) and fewer underwent disease progression (35.0 vs 43.6%). Subcutaneous administration was associated with a significantly lower incidence of grade 3 or 4 adverse events (46 vs 76%; P<0.001), and fewer s.c. patients required dose reductions because of toxicity (20 vs 82%). At the doses and within the schedules tested, this comparative analysis did not detect any difference in efficacy between s.c. and c.i.v. administration of rIL-2 in terms of overall survival, duration of response and response rate in patients with metastatic renal cell carcinoma. However, s.c. delivery of rIL-2 was associated with improved tolerability.
format Text
id pubmed-2409650
institution National Center for Biotechnology Information
language English
publishDate 2004
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-24096502009-09-10 Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinoma Geertsen, P F Gore, M E Negrier, S Tourani, J M von der Maase, H Br J Cancer Clinical A retrospective analysis was conducted on data from four open-label, nonrandomised, phase II trials of recombinant interleukin-2 (rIL-2) in patients with metastatic renal cell carcinoma to compare the safety and efficacy of administration by subcutaneous (s.c.) and continuous intravenous (c.i.v.) infusion (n=103 s.c. and n=225 c.i.v.). No statistically significant differences were found between the cohorts in terms of overall response rate (s.c.: 13.6% vs c.i.v.: 12.4%, P=0.77), response duration (s.c.: 9.8 months vs c.i.v.: 10.1 months, P=0.99), and overall survival (P=0.08). Compared with c.i.v. administration, more patients in the s.c. cohort experienced stable disease (50.5 vs 29.8%) and fewer underwent disease progression (35.0 vs 43.6%). Subcutaneous administration was associated with a significantly lower incidence of grade 3 or 4 adverse events (46 vs 76%; P<0.001), and fewer s.c. patients required dose reductions because of toxicity (20 vs 82%). At the doses and within the schedules tested, this comparative analysis did not detect any difference in efficacy between s.c. and c.i.v. administration of rIL-2 in terms of overall survival, duration of response and response rate in patients with metastatic renal cell carcinoma. However, s.c. delivery of rIL-2 was associated with improved tolerability. Nature Publishing Group 2004-03-22 2004-03-02 /pmc/articles/PMC2409650/ /pubmed/15026795 http://dx.doi.org/10.1038/sj.bjc.6601709 Text en Copyright © 2004 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Clinical
Geertsen, P F
Gore, M E
Negrier, S
Tourani, J M
von der Maase, H
Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinoma
title Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinoma
title_full Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinoma
title_fullStr Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinoma
title_full_unstemmed Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinoma
title_short Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinoma
title_sort safety and efficacy of subcutaneous and continuous intravenous infusion ril-2 in patients with metastatic renal cell carcinoma
topic Clinical
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409650/
https://www.ncbi.nlm.nih.gov/pubmed/15026795
http://dx.doi.org/10.1038/sj.bjc.6601709
work_keys_str_mv AT geertsenpf safetyandefficacyofsubcutaneousandcontinuousintravenousinfusionril2inpatientswithmetastaticrenalcellcarcinoma
AT goreme safetyandefficacyofsubcutaneousandcontinuousintravenousinfusionril2inpatientswithmetastaticrenalcellcarcinoma
AT negriers safetyandefficacyofsubcutaneousandcontinuousintravenousinfusionril2inpatientswithmetastaticrenalcellcarcinoma
AT touranijm safetyandefficacyofsubcutaneousandcontinuousintravenousinfusionril2inpatientswithmetastaticrenalcellcarcinoma
AT vondermaaseh safetyandefficacyofsubcutaneousandcontinuousintravenousinfusionril2inpatientswithmetastaticrenalcellcarcinoma